- Home
- TENB vs APLS Comparison
TENB vs APLS Comparison
Compare TENB & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENB
- APLS
- Stock Information
- Founded
- TENB 2002
- APLS 2009
- Country
- TENB United States
- APLS United States
- Employees
- TENB N/A
- APLS N/A
- Industry
- TENB Computer Software: Prepackaged Software
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- TENB Technology
- APLS Health Care
- Exchange
- TENB Nasdaq
- APLS Nasdaq
- Market Cap
- TENB 3.6B
- APLS 3.5B
- IPO Year
- TENB 2018
- APLS 2017
- Fundamental
- Price
- TENB $31.03
- APLS $27.60
- Analyst Decision
- TENB Buy
- APLS Buy
- Analyst Count
- TENB 17
- APLS 20
- Target Price
- TENB $41.06
- APLS $34.11
- AVG Volume (30 Days)
- TENB 1.4M
- APLS 2.3M
- Earning Date
- TENB 10-29-2025
- APLS 07-31-2025
- Dividend Yield
- TENB N/A
- APLS N/A
- EPS Growth
- TENB N/A
- APLS N/A
- EPS
- TENB N/A
- APLS N/A
- Revenue
- TENB $949,251,000.00
- APLS $754,649,000.00
- Revenue This Year
- TENB $11.66
- APLS $20.59
- Revenue Next Year
- TENB $7.86
- APLS N/A
- P/E Ratio
- TENB N/A
- APLS N/A
- Revenue Growth
- TENB 11.41
- APLS 20.02
- 52 Week Low
- TENB $28.51
- APLS $16.10
- 52 Week High
- TENB $45.45
- APLS $41.94
- Technical
- Relative Strength Index (RSI)
- TENB 53.60
- APLS 71.41
- Support Level
- TENB $29.55
- APLS $27.27
- Resistance Level
- TENB $31.07
- APLS $28.70
- Average True Range (ATR)
- TENB 0.77
- APLS 1.02
- MACD
- TENB 0.25
- APLS -0.05
- Stochastic Oscillator
- TENB 96.25
- APLS 83.89
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.